Inventor
WOELFEL THOMAS
DE19 patents
⚠️ This page may combine multiple inventors who share the name “WOELFEL THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LUDWIG INST CANCER RES
15 patentsUS5620886AApr 15, 1997
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES75 citations96
US5487974AJan 30, 1996
Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
LUDWIG INST CANCER RES59 citations95
US6201111B1Mar 13, 2001
Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
LUDWIG INST CANCER RES15 citations92
US5854203ADec 29, 1998
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES25 citations92
US5837476ANov 17, 1998
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
LUDWIG INST CANCER RES19 citations92
US5747271AMay 5, 1998
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES39 citations92
US5744316AApr 28, 1998
Isolated, tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES28 citations92
US5530096AJun 25, 1996
Isolated, tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES22 citations92
US5856091AJan 5, 1999
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES16 citations82
US6669946B2Dec 30, 2003
Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES5 citations73
US6001975ADec 14, 1999
Precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES15 citations72
US5519117AMay 21, 1996
Isolated, tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES10 citations70
US5843688ADec 1, 1998
Isolated tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES2 citations62
US6284476B1Sep 4, 2001
Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
LUDWIG INST CANCER RES0 citations51
US5843687ADec 1, 1998
Isolated, tyrosinase derived peptides and uses thereof
LUDWIG INST CANCER RES0 citations51